Preserving what makes people who they are
Neurological conditions can cause people’s identities to fade over time. For the first time in history, Roche has the tools, technology and scientific insights that we believe will lead to new types of medicines that can alter or even reverse the trajectory of neurological diseases.

This is why, at Roche, we are pursuing the immense challenges of neuroscience with curiosity, passion and rigour. Our research efforts are contributing to promising changes in the landscape of treatments for neurological disorders and MS – with newer medicines for MS showing that earlier initiation and continuation of treatment can reduce disability progression over a sustained period of time.

We have one of the most advanced neuroscience pipelines in the industry, with six late-stage investigational medicines in development, spanning the spectrum of nervous system disorders from the rarest to the most common – for conditions that include multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and autism.

Understanding progression in MS
This animation helps to explain what disease progression in MS is, how it works, and why it’s critical that to talk about it with a healthcare provider for a timely diagnosis and treatment.

The brain makes us who we are. It allows us to think, learn, feel, connect with others and make our way in the world. Illnesses that affect the brain and its connections to the body interrupt careers, burden families, cut individual ties to the world and can limit dreams for the future.

More stories

See all stories

please be aware that you are leaving this website.